Notably, the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial, the first dedicated kidney outcome trial evaluating canagliflozin in people with type 2 diabetes mellitus and CKD, demonstrated a substantial reduction in the risk of kidney events [46]
When considering which GLP-1 medication is best for you, the cost is a significant factor to explore
Bei einer atherosklerotischen cv Erkrankung mit einem T2DM u./od
Dias S, Sutton AJ, Ades AE, Welton NJ
Gut-brain axis: GLP-1 is a peptide hormone (a small protein molecule) that is released in the upper part of the intestinal tract when you eat carbohydrates or certain proteins
Patil HR, Al Badarin FJ, Al Shami HA, et al